Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Slightly Bullish +12

Aware Super Pty Ltd as trustee of Aware Super Takes Position in Bristol ...

AI-generated analysis

📈 Aware Super Pty Ltd acquired a new position of 328,003 shares valued at approximately $19.9 million in the first quarter.

🏦 Institutional ownership remains high at 76.41%, with other firms like Swiss RE and Darwin Wealth Management adding new stakes.

💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3rd to investors of record by July 2nd.

📊 Bristol Myers Squibb trades at a market cap of $123.48 billion with a P/E ratio of 16.99 and a beta of 0.23.

📉 The stock opened at $60.47, trading above its fifty-day moving average of $56.93 but below the 200-day average of $57.76.

🎯 Analyst consensus is currently a 'Hold' with an average price target of $61.25 based on data from MarketBeat.com.

📉 Bank of America reduced its price objective to $66 while maintaining a 'buy' rating in a recent research note.

⚖️ Cantor Fitzgerald reissued a 'neutral' rating with a lower price objective of $54.00 for the biopharmaceutical stock.

🔬 The company focuses on discovering and delivering medicines for serious diseases, specifically in oncology and immune-mediated conditions.

💸 The dividend payout ratio stands at 70.79%, representing an annualized yield of 4.2%.

Bullish Signals
  • Aware Super Pty Ltd established a significant new position valued at $19.9 million, indicating institutional confidence in the company's long-term prospects.
  • The company maintains a strong dividend profile with a 4.2% annualized yield and a payout ratio of 70.79%, providing steady income to shareholders.
  • UBS Group restated a 'buy' rating on the stock, signaling continued analyst support for Bristol Myers Squibb's strategic direction.
  • The firm holds a robust balance sheet with a quick ratio of 1.28 and a current ratio of 1.42, ensuring liquidity for ongoing operations.
Risk Factors
  • Cantor Fitzgerald issued a 'neutral' rating with a price objective of $54.00, which is significantly below the current trading price of approximately $60.
  • Bank of America reduced its price target from $67.00 to $66.00, suggesting potential downside pressure or a more conservative valuation outlook.
  • The stock trades below its 200-day moving average of $57.76, indicating some short-term weakness relative to longer-term trends.
  • Weiss Ratings restated a 'hold (c+)' rating, reflecting cautious sentiment among analysts regarding the company's immediate performance.
Full Analysis
Aware Super Pty Ltd increased its position in Bristol Myers Squibb (NYSE:BMY) by purchasing 328,003 shares valued at approximately $19.9 million during the first quarter. This move joins a list of other institutional investors, including Swiss RE and various wealth management firms, who have recently established or expanded stakes in the biopharmaceutical company, with hedge funds collectively owning 76.41% of the outstanding stock. Bristol Myers Squibb's stock opened at $60.47 on Friday, trading against a market capitalization of $123.48 billion and a price-to-earnings ratio of 16.99. The company recently declared a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd, resulting in an annualized yield of 4.2% with a payout ratio of 70.79%. Technical indicators show the stock trading above its fifty-day moving average but below its 200-day average. Analyst sentiment remains mixed regarding the company's future prospects. While UBS Group maintained a 'buy' rating and Bank of America lowered its price objective to $66, Cantor Fitzgerald issued a 'neutral' rating with a $54 target. The consensus among eight investment analysts is currently a 'Hold' with an average price target of $61.25. Bristol Myers Squibb continues to focus on its core portfolio in oncology and immune-mediated conditions through small molecules and biologics.